Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections

The effect of N-acetylcysteine in a combined antibiofilm treatment against antibiotic-resistant Staphylococcus aureus

(2020) Arthika Manoharan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient

(2020) Andrew B. Gainey et al.   PEDIATRIC PULMONOLOGY

Achromobacter Infections and Treatment Options

(2020) Burcu Isler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation—A proof-of-principle study in a P. aeruginosa lung infection model

(2020) Yu Lin et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome

(2019) Robert A. Quinn et al.   Microbiome

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

(2019) Vanessa E. Rees et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Changing Prevalence of Lower Airway Infections in Young Children with Cystic Fibrosis

(2019) Oded Breuer et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients

(2019) Rachel Yoon Kyung Chang et al.   AAPS Journal

Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient

(2019) Nancy Law et al.   INFECTION

Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine Against Biofilms of Five Common Pathogens

(2019) Yuanna Shen et al.   Microbial Drug Resistance

Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry

(2019) Elpis Hatziagorou et al.   Journal of Cystic Fibrosis

Conditions Under Which Glutathione Disrupts the Biofilms and Improves Antibiotic Efficacy of Both ESKAPE and Non-ESKAPE Species

(2019) Theerthankar Das et al.   Frontiers in Microbiology

Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population

(2019) Mark A. Tesell et al.   Journal of Managed Care & Specialty Pharmacy

A putative enoyl-CoA hydratase contributes to biofilm formation and the antibiotic tolerance of Achromobacter xylosoxidans

(2019) Lydia C. Cameron et al.   npj Biofilms and Microbiomes

Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis

(2019) Nashrawan Lababidi et al.   JOURNAL OF CONTROLLED RELEASE

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Long-term Microevolution of Pseudomonas aeruginosa Differs Between Mildly and Severely Affected Cystic Fibrosis Lungs

(2018) Jens Klockgether et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens

(2018) Parth N. Shah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics

(2018) Valerie Defraine et al.   DRUG RESISTANCE UPDATES

Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis

(2018) Konstantinos Z. Vardakas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Eradication of early P. aeruginosa infection in children

(2018) Felix Ratjen et al.   Journal of Cystic Fibrosis

Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis

(2018) S.L. Heltshe et al.   Journal of Cystic Fibrosis

Quorum-Sensing Systems as Targets for Antivirulence Therapy

(2018) Tom Defoirdt   TRENDS IN MICROBIOLOGY

Electrochemically Synthesized Silver Nanoparticles Are Active Against Planktonic and Biofilm Cells of Pseudomonas aeruginosa and Other Cystic Fibrosis-Associated Bacterial Pathogens

(2018) Arianna Pompilio et al.   Frontiers in Microbiology

Impact of gram negative bacteria airway recolonization on the occurrence of chronic lung allograft dysfunction after lung transplantation in a population of cystic fibrosis patients

(2018) Sarah Orfanos et al.   BMC MICROBIOLOGY

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1

(2018) Susanna A. McColley et al.   Journal of Cystic Fibrosis

Burkholderia cepacia complex infections: More complex than the bacterium name suggest

(2018) Maroun M. Sfeir   JOURNAL OF INFECTION

In vitro activity of N-acetylcysteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and biofilm

(2018) Simona Pollini et al.   PLoS One

Investigating the Mechanism of Action of Diketopiperazines Inhibitors of the Burkholderia cenocepacia Quorum Sensing Synthase CepI: A Site-Directed Mutagenesis Study

(2018) Silvia Buroni et al.   Frontiers in Pharmacology

Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS): A Randomized, Double-Blind, Controlled Study

(2018) Mirjam Stahl et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Elimination of Australian epidemic strain (AES1) pseudomonas aeruginosa in a pediatric cystic fibrosis center

(2018) Ajay Kevat et al.   PEDIATRIC PULMONOLOGY

Hypoxia and the hypoxia-regulated transcription factor HIF-1α suppress the host defence of airway epithelial cells

(2017) Markus Polke et al.   Innate Immunity

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

(2017) Diego Maselli et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Flavonoids SuppressPseudomonas aeruginosaVirulence through Allosteric Inhibition of Quorum-sensing Receptors

(2017) Jon E. Paczkowski et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

(2017) Barry J Plant et al.   Journal of Cystic Fibrosis

Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis

(2017) Ana C. Blanchard et al.   Journal of Cystic Fibrosis

Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment

(2017) Laia Fernández-Barat et al.   Journal of Cystic Fibrosis

The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis

(2017) Katherine B Frayman et al.   THORAX

Low Concentrations of Vitamin C Reduce the Synthesis of Extracellular Polymers and Destabilize Bacterial Biofilms

(2017) Santosh Pandit et al.   Frontiers in Microbiology

Glutathione Enhances Antibiotic Efficiency and Effectiveness of DNase I in Disrupting Pseudomonas aeruginosa Biofilms While Also Inhibiting Pyocyanin Activity, Thus Facilitating Restoration of Cell Enzymatic Activity, Confluence and Viability

(2017) Theerthankar Das et al.   Frontiers in Microbiology

A broad range quorum sensing inhibitor working through sRNA inhibition

(2017) Tim H. Jakobsen et al.   Scientific Reports

Clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis from a center with a high MRSA prevalence

(2016) Nada S. Harik et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates

(2016) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Glutathione-Disrupted Biofilms of Clinical Pseudomonas aeruginosa Strains Exhibit an Enhanced Antibiotic Effect and a Novel Biofilm Transcriptome

(2016) William Klare et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis

(2016) Elizabeth L. Salsgiver et al.   CHEST

The Approach to Pseudomonas aeruginosa in Cystic Fibrosis

(2016) Jaideep S. Talwalkar et al.   CLINICS IN CHEST MEDICINE

Pseudomonas aeruginosabiofilm disruption using microbial surfactants

(2016) M.A. Díaz De Rienzo et al.   JOURNAL OF APPLIED MICROBIOLOGY

Acidic pH increases airway surface liquid viscosity in cystic fibrosis

(2016) Xiao Xiao Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis

(2016) C. Van de Kerkhove et al.   Journal of Cystic Fibrosis

The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections

(2016) Francesco Blasi et al.   RESPIRATORY MEDICINE

Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo

(2016) Viola C. Scoffone et al.   Scientific Reports

The nasal microbiota in infants with cystic fibrosis in the first year of life: a prospective cohort study

(2016) Moana Mika et al.   Lancet Respiratory Medicine

Effect of common and experimental anti-tuberculosis treatments onMycobacterium tuberculosisgrowing as biofilms

(2016) James P. Dalton et al.   PeerJ

The Effect of Strict Segregation on Pseudomonas aeruginosa in Cystic Fibrosis Patients

(2016) Rosa van Mansfeld et al.   PLoS One

The Quorum Sensing Inhibitor Hamamelitannin Increases Antibiotic Susceptibility of Staphylococcus aureus Biofilms by Affecting Peptidoglycan Biosynthesis and eDNA Release

(2016) Gilles Brackman et al.   Scientific Reports

Impact of Sustained Eradication of NewPseudomonas aeruginosaInfection on Long-term Outcomes in Cystic Fibrosis

(2015) Nicole Mayer-Hamblett et al.   CLINICAL INFECTIOUS DISEASES

Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis

(2015) P. Vidya et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: Formulation, characterisation and functionalisation with dornase alfa (DNase)

(2015) Jill Deacon et al.   JOURNAL OF CONTROLLED RELEASE

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial

(2015) C. Conrad et al.   Journal of Cystic Fibrosis

The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure

(2015) Roger D. Yusen et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

(2015) David Weill et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Fitness trade-offs explain low levels of persister cells in the opportunistic pathogenPseudomonas aeruginosa

(2015) Kristine Stepanyan et al.   MOLECULAR ECOLOGY

Degradable polyphosphoester-based silver-loaded nanoparticles as therapeutics for bacterial lung infections

(2015) Fuwu Zhang et al.   Nanoscale

Acute toxicity of silver and carbon nanoaerosols to normal and cystic fibrosis human bronchial epithelial cells

(2015) Natalie Jeannet et al.   Nanotoxicology

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

(2015) Claire E. Wainwright et al.   NEW ENGLAND JOURNAL OF MEDICINE

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary

(2015) R Andres Floto et al.   THORAX

Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status

(2015) Jean-Marc Rolain et al.   Drug Design Development and Therapy

Nontypeable Haemophilus influenzae Induces Sustained Lung Oxidative Stress and Protease Expression

(2015) Paul T. King et al.   PLoS One

Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation

(2015) Cédric Bernarde et al.   PLoS One

Synergy of Silver Nanoparticles and Aztreonam against Pseudomonas aeruginosa PAO1 Biofilms

(2014) Marc B. Habash et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Aerosol Phage Therapy Efficacy in Burkholderia cepacia Complex Respiratory Infections

(2014) Diana D. Semler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recent advances in the management of cystic fibrosis

(2014) J. C. Davies et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Oropharyngeal and nasal Staphylococcus aureus carriage by healthy children

(2014) Susanna Esposito et al.   BMC INFECTIOUS DISEASES

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

(2014) Sonya L. Heltshe et al.   CLINICAL INFECTIOUS DISEASES

CFTR: cystic fibrosis and beyond

(2014) M. A. Mall et al.   EUROPEAN RESPIRATORY JOURNAL

Effects of airway surface liquid pH on host defense in cystic fibrosis

(2014) Abigail R. Berkebile et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure

(2014) Ashley G. Henderson et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)

(2014) M.J. Harrison et al.   Journal of Cystic Fibrosis

Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis

(2014) Rasmus Lykke Marvig et al.   NATURE GENETICS

The clinical relevance of dry powder inhaler performance for drug delivery

(2014) Pascal Demoly et al.   RESPIRATORY MEDICINE

Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis

(2014) M. J. Hoegger et al.   SCIENCE

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

(2014) Edward F McKone et al.   Lancet Respiratory Medicine

Cystic Fibrosis Pulmonary Guidelines

(2013) Peter J. Mogayzel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Anti-biofilm activities of quercetin and tannic acid againstStaphylococcus aureus

(2013) Jin-Hyung Lee et al.   BIOFOULING

Lung transplant outcomes in cystic fibrosis patients with pre-operativeMycobacterium abscessusrespiratory infections

(2013) Leonard J. Lobo et al.   CLINICAL TRANSPLANTATION

Virulence factor expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis

(2013) J. Manos et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Respirable Bacteriophages for the Treatment of Bacterial Lung Infections

(2013) Susan Hoe et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients from Two Brazilian Cities

(2013) Larissa Lutz et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

(2013) Valerie Waters et al.   Journal of Cystic Fibrosis

Phenotypic and Genotypic Characterisation of Burkholderia cenocepacia J2315 Mutants Affected in Homoserine Lactone and Diffusible Signal Factor-Based Quorum Sensing Systems Suggests Interplay between Both Types of Systems

(2013) Claudia Udine et al.   PLoS One

Structures and biofilm inhibition activities of brominated furanones for Escherichia coli and Pseudomonas aeruginosa

(2013) Gauri S. Shetye et al.   MedChemComm

Two quorum sensing systems control biofilm formation and virulence in members of theBurkholderia cepaciacomplex

(2013) Angela Suppiger et al.   Virulence

Antibiotic and Anti-Inflammatory Therapies for Cystic Fibrosis

(2013) J. F. Chmiel et al.   Cold Spring Harbor Perspectives in Medicine

Ajoene, a Sulfur-Rich Molecule from Garlic, Inhibits Genes Controlled by Quorum Sensing

(2012) Tim Holm Jakobsen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Food as a Source for Quorum Sensing Inhibitors: Iberin from Horseradish Revealed as a Quorum Sensing Inhibitor of Pseudomonas aeruginosa

(2012) Tim Holm Jakobsen et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Antibacterial effects of silver nanoparticles on gram-negative bacteria: Influence on the growth and biofilms formation, mechanisms of action

(2012) M.A. Radzig et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Dornase alfa (Pulmozyme)

(2012) Jeffrey S. Wagener et al.   CURRENT OPINION IN PULMONARY MEDICINE

New Therapies in Cystic Fibrosis

(2012) Felix Ratjen et al.   CURRENT PHARMACEUTICAL DESIGN

Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa

(2012) Petra Schelstraete et al.   Journal of Cystic Fibrosis

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis

(2012) Jeffrey S. Wagener et al.   PEDIATRIC PULMONOLOGY

Vitamin C Inhibits Staphylococcus aureus Growth and Enhances the Inhibitory Effect of Quercetin on Growth of Escherichia coli In Vitro

(2012) Johanna Kallio et al.   PLANTA MEDICA

The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of Exacerbations

(2012) Anthony A. Fodor et al.   PLoS One

Exercise with incorporated expiratory manoeuvres was as effective as breathing techniques for airway clearance in children with cystic fibrosis: a randomised crossover trial

(2012) Philippe Reix et al.   Journal of Physiotherapy

Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis

(2011) Naveen Pillarisetti et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis

(2011) Miriam M. Treggiari   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus

(2011) Scott N Dean et al.   BMC MICROBIOLOGY

Role of Antibiofilm-Antimicrobial Agents in Controlling Device-Related Infections

(2011) Saima Aslam et al.   INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS

Haemophilus influenzae in children with cystic fibrosis: Antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation

(2011) Rita Cardines et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

An investigation on the antibacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles

(2011) Soumitra Mohanty et al.   Nanomedicine-Nanotechnology Biology and Medicine

Pseudomonas aeruginosa: all roads lead to resistance

(2011) Elena B.M. Breidenstein et al.   TRENDS IN MICROBIOLOGY

N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa

(2010) Tiemei Zhao et al.   BMC MICROBIOLOGY

In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis

(2010) L. Golshahi et al.   JOURNAL OF APPLIED MICROBIOLOGY

Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: A single-center experience

(2010) Anthony De Soyza et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Bacteriophages Can Treat and PreventPseudomonas aeruginosaLung Infections

(2010) Laurent Debarbieux et al.   JOURNAL OF INFECTIOUS DISEASES

Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening

(2010) Joe J Harrison et al.   Nature Protocols

Airway Microbiota and Pathogen Abundance in Age-Stratified Cystic Fibrosis Patients

(2010) Michael J. Cox et al.   PLoS One

Cystic Fibrosis Pulmonary Guidelines

(2009) Patrick A. Flume et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

(2009) F. Ratjen et al.   THORAX

Human Host Defense Peptide LL-37 Prevents Bacterial Biofilm Formation

(2008) J. Overhage et al.   INFECTION AND IMMUNITY

Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation

(2008) A. Mena et al.   JOURNAL OF BACTERIOLOGY

Association between Hypermutator Phenotype, Clinical Variables, Mucoid Phenotype, and Antimicrobial Resistance in Pseudomonas aeruginosa

(2008) D. J. Waine et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Segregation is not good for patients with cystic fibrosis

(2008) Duncan Geddes   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Segregation is good for patients with cystic fibrosis

(2008) Steven Conway   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

(2008) Irene Krämer et al.   PEDIATRIC PULMONOLOGY

Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis

(2008) J. Gottlieb et al.   RESPIRATORY MEDICINE